New drug for B-cell lymphoma that returned after treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma that has come back or hasn't responded to 2 or more prior treatments.
- You should be able to care for yourself (ECOG score 0-2) and have a life expectancy of at least 3 months.
- You need to have at least one tumor that can be measured on scans.
- Your blood counts (neutrophils, platelets, hemoglobin) and kidney/liver function must be within certain limits.
- You cannot have lymphoma that has spread to the brain or spinal cord.
- You must not have received a prior stem cell transplant from a donor or certain types of blood-related therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests a new injectable treatment (called JY231) for people whose B-cell lymphoma has come back or did not respond to standard treatments. The treatment targets a specific marker on cancer cells (CD19) and may help when other options have not worked.
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
This trial tests an experimental drug called BTM-3566 in people with a type of lymphoma that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.